person
as of 2026-07-01Alan I. Green, MD
Alan Green, MDAlan I Green, MD
at a glance
Roles: Principal Investigator, Study Chair
KOL signal score 5
0 publications · 0 high-value
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Dartmouth-Hitchcock Medical Center
Roles
Principal Investigator, Study Chair
KOL signal
5
Publications
0 (0 high-value)
Trial investigator
yes
Trials led
11
Risperidone and Desipramine in Alcohol Use and Schizophrenia
NCT01411085Phase 2Completed
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169039Phase 4Terminated
Clozapine for Cannabis Use in Schizophrenia
NCT01639872Phase 4Completed
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00130923Phase 4Completed
First Episode Schizophrenia and Cannabis-Related Disorder Study
NCT00573287—Completed
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
NCT00498550Phase 4Completed
Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169026Phase 4Terminated
Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00169091Phase 4Terminated
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00156715Phase 4Completed
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
NCT00946348Phase 1Completed
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169065Phase 4Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
PRINCIPAL_INVESTIGATOR
STUDY_CHAIR